DNA hypomethylation makes humans prone to diseases
Enlarge image


DNA hypomethylation makes humans prone to diseases

22.05.2012 - A Polish-US research team has found that hypomethylation destablises DNA and boosts the risk of neurological diseases.

Warsaw/Houston –Bioinformaticians from Warsaw University and the Baylor College of Medicine have provided an explanation for how disease-associated mutation hotspots may arise. According to results of the group under Aleksandar Milosavljevic and Tomasz Gambin, regions on human chromosomes that carry only few so-called methylation marks show a tenfold higher number of structural mutations than the genome-wide average. Patients diagnosed with schizophrenia, bipolar disorder, developmental delay, and autism had a significant higher amount of such predetermined breaking points, (PloS Genetics 8(5): e1002692).

The researchers suggest that the amount of methylation might mediate genomic stability.  They compared methylome maps from human sperm cell samples with publicly available structural variation data. Their results points to a strong association of germline hypomethylation and genomic instability which might lead to new diagnostic and therapeutic approaches. "We have found that these rare and de novo structural variants, as well as changes of the human genome that have accumulated the fastest since the branching chimpanzee, are significantly concentrated within methylation deserts," senior author Aleksandar Milosavljevic, a molecular and human genetics researcher at Baylor College of Medicine, said in a statement.

Lack of methylation of genomic DNA has been previously associated with high structural mutability in gibbons and in human cancer cells, but the association with structural mutability in the human germline has not been explored prior to this study.


26.11.2015 Bioeconomy movers and shakers from every corner of the globe met this week at the world’s first Global Bioeconomy Summit in Berlin to discuss, debate and define better ways to ensure the bioeconomy succeeds on an international level.


24.11.2015 After weeks of speculation it is official: US pharma major Pfizer and Irish Botox maker Allergan will merge. With the deal, Pfizer is planning to dodge the high US taxes, causing indignation among US politicians.


23.11.2015 Amidst talk of the IPO window closing and cancelled flotations, diagnostics firms are still striking a chord with investors. Swedish Immunovia and German Curetis are successfully raising public money.


20.11.2015 French Sanofi and British AstraZeneca are giving open innovation a go: The two pharma giants will exchange thousands of compounds – for free.


19.11.2015 French gene editing company Cellectis has granted Servier the rights to bring cancer immunotherapy UCART19 to market. Servier in turn has teamed up with Pfizer to hurry development along.


17.11.2015 The first Italian accelerator specifically for biotech projects has been launched with help from Sofinnova Partners. The plan of BiovelocITA: to help Italy grow into one of Europe’s strongest biotech markets.


13.11.2015 Scientists in Bath, UK, have developed a medical dressing that turns fluorescent green when it detects infection. The researchers hope that the smart burns dressing will help fight antibiotic resistance.


13.11.2015 Out with the old: Roche is discarding four sites with 1,200 staff in an effort to restructure its manufacturing network for small molecules. Instead, a new manufacturing site will be built in Switzerland.


10.11.2015 Algae have many skills, but cancer fighting was not one of them – until now. Researchers from Australia and Germany have genetically engineered diatom algae to accurately deliver chemotherapeutic drugs.


10.11.2015 AstraZeneca has plucked Californian biopharma company ZS Pharma from under Actelion’s nose. The UK company is paying US$2.7bn (€2.5bn) to acquire ZS and its promising hyperkalaemia treatment currently under US regulatory review.


All Events


Strasbourg (F)

BioFIT 2015

Current issue

All issues

Product of the week


Stock list

All quotes


  • DIAMYD MEDICAL -B- (S)10.00 SEK14.29%
  • SERODUS (N)2.67 NOK9.43%


  • EVOCUTIS (UK)0.09 GBP-10.00%
  • VERONA PHARMA (UK)3.05 GBP-6.15%
  • SAREUM HOLDINGS (UK)0.19 GBP-5.00%


  • PLETHORA (UK)5.62 GBP80.1%
  • PROTHENA PLC (IE)73.19 USD40.9%
  • CELLECTIS (F)30.70 EUR32.3%


  • EPIGENOMICS (D)1.87 EUR-58.5%
  • EVOCUTIS (UK)0.09 GBP-40.0%


  • KARO BIO (S)38.10 SEK5342.9%
  • CHRONTECH PHARMA (S)0.34 SEK1600.0%
  • GALAPAGOS (B)45.70 EUR254.3%


  • BIOTEST (D)15.34 EUR-81.0%
  • EVOCUTIS (UK)0.09 GBP-78.6%

No liability assumed, Date: 26.11.2015